A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
A phase 3 trial of Bel-sar in uveal melanoma, run by Aura Biosciences, active and no longer recruiting.
Overview
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma is a phase 3 interventional study registered as NCT06007690 by Aura Biosciences, with 108 participants enrolled, started 2023-12-06 and due to reach its primary completion in 2027-11-15. Interventions recorded: Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser and Sham Microinjector.
Similar pages
not linked directly; found by shared links- TrialSuprachoroidal Administration in Subjects With Metastases to the Choroid
Shares Aura Biosciences and the tag pipeline.
- TrialEvaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Shares Uveal melanoma and the tag pipeline.
- TrialA Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
Shares Uveal melanoma and the tag pipeline.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Uveal melanoma and the tag pipeline.
- TrialA Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Shares Uveal melanoma and the tag pipeline.
- TrialA Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
Shares Uveal melanoma and the tag pipeline.
- TreatmentDarovasertib
Shares Uveal melanoma and the tag pipeline.